Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Total Current Liabilities (2016 - 2025)

Historic Total Current Liabilities for Niagen Bioscience (NAGE) over the last 15 years, with Q3 2025 value amounting to $22.7 million.

  • Niagen Bioscience's Total Current Liabilities rose 2832.36% to $22.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $22.7 million, marking a year-over-year increase of 2832.36%. This contributed to the annual value of $17.9 million for FY2024, which is 1296.67% down from last year.
  • As of Q3 2025, Niagen Bioscience's Total Current Liabilities stood at $22.7 million, which was up 2832.36% from $22.3 million recorded in Q2 2025.
  • In the past 5 years, Niagen Bioscience's Total Current Liabilities ranged from a high of $22.7 million in Q3 2025 and a low of $16.2 million during Q2 2021
  • Moreover, its 5-year median value for Total Current Liabilities was $18.2 million (2023), whereas its average is $18.8 million.
  • Its Total Current Liabilities has fluctuated over the past 5 years, first crashed by 1296.67% in 2024, then skyrocketed by 2832.36% in 2025.
  • Niagen Bioscience's Total Current Liabilities (Quarter) stood at $17.6 million in 2021, then increased by 1.45% to $17.9 million in 2022, then rose by 15.41% to $20.6 million in 2023, then decreased by 12.97% to $17.9 million in 2024, then rose by 26.54% to $22.7 million in 2025.
  • Its last three reported values are $22.7 million in Q3 2025, $22.3 million for Q2 2025, and $20.8 million during Q1 2025.